Amsterdam, the Netherlands, September 26, 2007 - Akzo Nobel has today released a proposed timetable of the key dates regarding the company's recommended cash offer for ICI, which was announced on August 13.
Akzo Nobel intends to post its Shareholder Circular on October 1, 2007. In addition, the company will be holding an Analyst & Media Day in London on October 8, followed by a similar event in New York on October 9.
At that event the company will further explain the strategy behind the offer for ICI and elaborate on the financial strategy for the company going forward.
An Extraordinary General Meeting of Shareholders (EGM) of Akzo Nobel is scheduled for
November 5 in Amsterdam, the Netherlands.
Further details will follow in due course.
- - -
Note to editors
Akzo Nobel is a Fortune Global 500 company and is listed on Euronext Amsterdam. It is also the Chemicals Industry leader on the Dow Jones Sustainability Indexes and Akzo Nobel is included on the FTSE4Good Index. Based in the Netherlands, we are a multicultural organization serving customers throughout the world with coatings, chemicals and human and animal healthcare products. We employ around 62,000 people and conduct our activities in these four segments, with operating subsidiaries in more than 80 countries. Consolidated revenues for 2006 totaled EUR 13.7 billion. The financial results for the third quarter will be published on October, 23, 2007.
Internet: www.akzonobel.com
Not for publication - for more information
Akzo Nobel nv
Corporate Media Relations, tel. +31 20 502 7833
Contact: Tim van der Zanden
Safe Harbor Statement*
This press release may contain statements which address such key issues as Akzo Nobel's growth strategy, future financial results, market positions, product development, pharmaceutical products in the pipeline, and product approvals. Such statements should be carefully considered, and it should be understood that many factors could cause forecasted and actual results to differ from these statements. These factors include, but are not limited to, price fluctuations, currency fluctuations, progress of drug development, clinical testing and regulatory approval, developments in raw material and personnel costs, pensions, physical and environmental risks, legal issues, and legislative, fiscal, and other regulatory measures. Stated competitive positions are based on management estimates supported by information provided by specialized external agencies. For a more comprehensive discussion of the risk factors affecting our business please see our Annual Report on Form 20-F filed with the United States Securities and Exchange Commission, a copy of which can be found on the company's corporate website www.akzonobel.com.
* Pursuant to the U.S. Private Securities Litigation Reform Act 1995.
